Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 8, 2012

JDRF, BD Expand Diabetes Collaboration to Develop Continuous Glucose Monitoring System

  • Diabetes research organization JDRF and Becton, Dickinson and Company (BD) have extended their existing type 1 diabetes collaboration to include further development of the latter’s next-generation continuous glucose-sensing platform. The technology is relevant to JDRF’s partnership with the Helmsley Charitable Trust (HCT), which aims to develop artificial pancreas systems that comprise continuous glucose measurement sensors to enable automatic delivery of the right amount of insulin.

    “Combined with our existing JDRF collaboration to develop microneedle insulin infusion, this latest collaboration with JDRF and The Helmsley Charitable Trust demonstrates the parties’ commitment to further improving the patient experience and enabling the artificial pancreas,” states Linda Tharby, president for diabetes care at BD Medical.

    Back in 2010 BD and JDRF established a collaboration focused on the development of products that deliver insulin from a pump to a patient in either an infusion set or patch-pump configuration. The research program was one of the first nonexclusive industry initiatives undertaken by JDRF as part of its Artificial Pancreas Project, which ultimately aims to speed the development of fully automated diabetes management systems.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »